Alkermes PLC
Closed
SectorHealthcare
45.82 -0.54
Overview
Share price change
24h
Min
45.62
Max
46
Income | 67M 501K |
|---|---|
Sales | 103M 496M |
P/E Sector Avg | 121.316 56.597 |
EPS | 0.52 |
Profit margin | 0.101 |
Employees | 2,050 |
EBITDA | 76M 54M |
Next Earnings | 27 paź 2026 |
|---|
Market Cap | -1.1B 7.7B |
|---|---|
Previous open | 46.36 |
Previous close | 45.82 |
News Sentiment
By Acuity
50%
50%
126 / 339 Ranking in Healthcare
Alkermes PLC Chart
Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.
Related News
Peer Comparison
Price change
Alkermes PLC Forecast
Sentiment
By Acuity
126 / 339 Ranking in Healthcare
News Sentiment
Neutral
Volatility
Below average
News Volume (RCV)
Below average
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About Alkermes PLC
Alkermes plc is a biopharmaceutical company. The Company is engaged in the researching, developing and commercializing pharmaceutical products that are designed to address medical needs of patients in therapeutic areas. The Company has a portfolio of marketed drug products and a clinical pipeline of products that address central nervous system (CNS) disorders, such as schizophrenia, depression, addiction and multiple sclerosis (MS). The Company's products include ARISTADA, VIVITROL, INVEGA SUSTENNA, XEPLION, INVEGA TRINZA, TREVICTA, RISPERDAL CONSTA, AMPYRA, FAMPYRA, BYDUREON, Aripiprazole lauroxil, ALKS 5461, ALKS 3831, ALKS 8700, ALKS 6428, ALKS 4230 and ALKS 7119. The Company's product platforms include injectable extended-release microsphere technology, LinkeRx technology, NanoCrystal technology and oral controlled release (OCR) technology. ARISTADA is an extended-release intramuscular injectable suspension for the treatment of schizophrenia.